18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: Comparison with conventional imaging techniques

Breast Cancer Research and Treatment

Volumn 131, Issue 1, 2012, Pages 117-126

  Koolen, Bas B ^a   Vrancken Peeters, Marie Jeanne T F D ^a   Aukema, Tjeerd S ^a   Vogel, Wouter V ^a   Oldenburg, Hester S A ^a   Van Der Hage, Jos A ^a   Hoefnagel, Cornelis A ^a   Stokkel, Marcel P M ^a   Loo, Claudette E ^a   Rodenhuis, Sjoerd ^a   Rutgers, Emiel J Th ^a   Valdés Olmos, Renato A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Breast cancer; Breast neoplasm; Conventional imaging; Dissemination; PET CT; Staging

Indexed keywords

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; ECHOGRAPHY; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER METASTASIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84856228700     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1767-9     Document Type: Article

References (37)

1. M Kaufmann GN Hortobagyi A Goldhirsch S Scholl A Makris P Valagussa, et al. 2006 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940 1949 16622270 10.1200/JCO.2005.02.6187 (Pubitemid 46638994)
2. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 9704717 1:CAS:528:DyaK1cXlsFCgurg%3D (Pubitemid 28363030)
3. JS Mieog JA van der Hage CJ van de Velde 2007 Neoadjuvant chemotherapy for operable breast cancer Br J Surg 94 1189 1200 17701939 10.1002/bjs.5894 1:STN:280:DC%2BD2srmslaktA%3D%3D (Pubitemid 47584766)
4. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 10080586 1:CAS:528:DyaK1MXht1Wmur4%3D (Pubitemid 29075229)
5. J Hannemann HM Oosterkamp CA Bosch A Velds LF Wessels C Loo, et al. 2005 Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 23 3331 3342 15908647 10.1200/JCO.2005.09.077 1:CAS:528:DC%2BD2MXlsVyiu70%3D
6. CE Loo ME Straver S Rodenhuis SH Muller J Wesseling MJ Vrancken Peeters KG Gilhuijs 2011 Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype J Clin Oncol 29 660 666 21220595 10.1200/JCO.2010.31.1258
7. R Samant P Ganguly 1999 Staging investigations in patients with breast cancer: the role of bone scans and liver imaging Arch Surg 134 551 553 10323429 10.1001/archsurg.134.5.551 1:STN:280:DyaK1M3lsFSjug%3D%3D (discussion 554) (Pubitemid 29218128)
8. V Rondeau S Mathoulin-Pélissier L Tanneau AJ Sasco G MacGrogan M Debled 2010 Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death BMC Cancer 10 697 21194468 10.1186/1471-2407-10-697
9. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 2.2011. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed 22 Jun 2011
10. Dutch National Guideline for the Treatment of Breast Cancer, Version 1.1 (Sept 2008). http://www.oncoline.nl/mammacarcinoom. Accessed 22 Jun 2011
11. AR Kasem A Desai S Daniell P Sinha 2006 Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer Breast J 12 544 548 17238984 10.1111/j.1524-4741.2006.00343.x (Pubitemid 44690843)
12. J Dose C Bleckmann S Bachmann KH Bohuslavizki J Berger L Jenicke CR Habermann F Jänicke 2002 Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients Nucl Med Commun 23 857 864 12195090 10.1097/00006231-200209000-00009 1:CAS:528:DC%2BD38Xntlyhsb0%3D
13. D Fuster J Duch P Paredes M Velasco M Muñoz G Santamaría M Fontanillas F Pons 2008 Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures J Clin Oncol 26 4746 4751 18695254 10.1200/JCO.2008.17.1496
14. TA Heusner S Kuemmel L Umutlu A Koeninger LS Freudenberg EA Hauth, et al. 2008 Breast cancer staging in a single session: whole-body PET/CT mammography J Nucl Med 49 1215 1222 18632831 10.2967/jnumed.108.052050
15. S Mahner S Schirrmacher W Brenner L Jenicke CR Habermann N Avril J Dose-Schwarz 2008 Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-d-glucose, conventional imaging and computed tomography for staging of breast cancer Ann Oncol 19 1249 1254 18356138 10.1093/annonc/mdn057 1:STN:280:DC%2BD1cvgvVyisQ%3D%3D (Pubitemid 351911953)
16. TS Aukema EJ Rutgers WV Vogel HJ Teertstra HS Oldenburg MT Vrancken Peeters, et al. 2010 The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques Eur J Surg Oncol 36 387 392 19962268 10.1016/j.ejso.2009.11.009 1:STN:280: DC%2BC3c3gtVCgsA%3D%3D
17. PG Morris C Lynch JN Feeney S Patil J Howard SM Larson, et al. 2010 Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer J Clin Oncol 28 3154 3159 20516453 10.1200/JCO.2009.27.5743
18. I Segaert F Mottaghy S Ceyssens W De Wever S Stroobants C Van Ongeval, et al. 2010 Additional value of PET-CT in staging of clinical stage IIB and III breast cancer Breast J 16 617 624 21070439 10.1111/j.1524-4741.2010.00987.x
19. JJ van der Hoeven NC Krak OS Hoekstra EF Comans RP Boom D van Geldere, et al. 2004 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer J Clin Oncol 22 1253 1259 15051773 10.1200/JCO.2004.07.058 (Pubitemid 41079839)
20. JW Fletcher B Djulbegovic HP Soares BA Siegel VJ Lowe GH Lyman, et al. 2008 Recommendations on the use of 18F-FDG PET in oncology J Nucl Med 49 480 508 18287273 10.2967/jnumed.107.047787 (Pubitemid 351355215)
21. NC Hodgson KY Gulenchyn 2008 Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 26 712 720 18258978 10.1200/JCO.2007.13.8412 (Pubitemid 351264383)
22. N Niikura NT Ueno 2010 The role of F-FDG-positron emission tomography/computed tomography in staging primary breast cancer J Cancer 1 51 53 20842224
23. N Avril CA Rosé M Schelling J Dose W Kuhn S Bense, et al. 2000 Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 3495 3502 11032590 1:STN:280:DC%2BD3M%2Fhsl2hsA%3D%3D
24. G Antoch N Saoudi H Kuehl G Dahmen SP Mueller T Beyer, et al. 2004 Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET J Clin Oncol 22 4357 4368 15514377 10.1200/JCO.2004.08.120 (Pubitemid 41185156)
25. H Kennecke R Yerushalmi R Woods MCU Cheang D Voduc CH Speers TO Nielsen K Gelmon 2010 Metastatic behavior of breast cancer subtypes J Clin Oncol 28 3271 3277 20498394 10.1200/JCO.2009.25.9820
26. S Krüger AK Buck FM Mottaghy E Hasenkamp S Pauls C Schumann, et al. 2009 Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT Eur J Nucl Med Mol Imaging 36 1807 1812 19504092 10.1007/s00259-009-1181-2
27. I Ak MC Sivrikoz E Entok E Vardareli 2010 Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography Eur J Cardiothorac Surg 37 792 796 20015657 10.1016/j.ejcts.2009.11.011
28. GJ Cook S Houston R Rubens MN Maisey I Fogelman 1998 Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions J Clin Oncol 16 3375 3379 9779715 1:STN:280:DyaK1cvltV2qtw%3D%3D (Pubitemid 28481635)
29. TS Aukema ME Straver MJ Peeters NS Russell KG Gilhuijs WV Vogel EJ Rutgers RA Olmos 2010 Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer Eur J Cancer 46 3205 3210 20719497 10.1016/j.ejca.2010.07.034
30. U Veronesi C De Cicco VE Galimberti Jr. Fernandez N Rotmensz G Viale, et al. 2007 A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases Ann Oncol 18 473 478 17164229 10.1093/annonc/mdl425 1:STN:280:DC%2BD2szlt1ajtg%3D%3D (Pubitemid 46359625)
31. ME Straver TS Aukema RA Olmos EJ Rutgers KG Gilhuijs ME Schot WV Vogel MJ Peeters 2010 Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients Eur J Nucl Med Mol Imaging 37 1069 1076 20130860 10.1007/s00259-009-1343-2
32. GM McDermott A Welch RT Staff FJ Gilbert L Schweiger SI Semple, et al. 2007 Monitoring primary breast cancer throughout chemotherapy using FDG-PET Breast Cancer Res Treat 102 75 84 16897427 10.1007/s10549-006-9316-7 1:CAS:528:DC%2BD2sXhslCltrg%3D (Pubitemid 46294965)
33. N Avril S Sassen R Roylance 2009 Response to therapy in breast cancer J Nucl Med 50 Suppl 1 55S 63S 19380410 10.2967/jnumed.108.057240 1:CAS:528:DC%2BD1MXmtFahsbs%3D
34. J Duch D Fuster M Muñoz PL Fernández P Paredes M Fontanillas, et al. 2009 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer Eur J Nucl Med Mol Imaging 36 1551 1557 19326117 10.1007/s00259-009-1116-y 1:CAS:528:DC%2BD1MXht1WhtL3L
35. A Kumar R Kumar V Seenu SD Gupta M Chawla A Malhotra SN Mehta 2009 The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur Radiol 19 1347 1357 19214522 10.1007/s00330-009-1303-z
36. J Schwarz-Dose M Untch R Tiling S Sassen S Mahner S Kahlert, et al. 2009 Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose J Clin Oncol 27 535 541 19075273 10.1200/JCO.2008.17. 2650
37. AA Martoni C Zamagni S Quercia M Rosati N Cacciari A Bernardi, et al. 2010 Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy Cancer 116 805 813 20052718 10.1002/cncr.24820